NRG Therapeutics unpacks the molecular switch behind its ALS drug candidate, adding fresh mechanistic evidence to a trial already underway.
Longevity.Technology has been following NRG5051 since the earliest days of its preclinical story, through a Parkinson’s UK partnership, a $68.1 million (£50 million) Series B and, this January, the dosing of its first clinical trial volunteers. This week’s update fills in a piece of the puzzle that had, until now, remained something of a black box: exactly how the drug does what it does.
At the ALS Association’s ALS Nexus conference in late August, Stevenage-based NRG Therapeutics presented new data identifying the precise molecular gatekeeper its lead candidate works through [1].
Deep inside every cell’s mitochondria sits a structure called the mitochondrial permeability transition pore, or mPTP. Think of it as an emergency hatch. Under stress, it’s supposed to open briefly and close again. In neurodegenerative disease, it gets stuck open and that failure floods the cell with the kind of damage that eventually kills it. NRG5051 was designed to keep that hatch shut.
What the company didn’t fully know until now was which protein actually controls the hatch. NRG’s scientists, working with collaborators at the Melbourne-based WEHI – Walter and Eliza Hall Institute of Medical Research, say they’re among the first to pin that role on a protein called NLRX1 – part of a family that normally helps cells sense stress and mount immune responses. NLRX1 turns out to be the odd one out in that family: the only member that actually lives inside the mitochondria itself, sitting right at the site where the damage begins.
It gives NRG5051 a specific, druggable target rather than a vague “protect the mitochondria” strategy. In mouse models of ALS, the company reported, the drug produced marked anti-inflammatory and neuroprotective effects, including a drop in plasma neurofilament light chain, a blood marker doctors already use in the clinic to gauge how much nerve damage a patient is sustaining.
Why the target keeps showing up
The pore itself has a well-established villain to answer for. A misfolded protein called TDP-43 – found tangled up in mitochondria in the vast majority of ALS cases – appears to force the pore open, triggering the kind of cellular energy crisis and inflammatory spiral that eventually kills motor neurons. If NLRX1 really is the switch that lets TDP-43 do that damage, blocking it becomes a rational way to interrupt the disease rather than simply manage its symptoms.
“Alongside advancing NRG5051 through preclinical studies and now into human clinical trials, we are pleased to have unravelled its novel mode of action in modulating the mPTP,” said Neil Miller, NRG’s co-founder and CEO. “Prevention of mPTP opening, via NLRX1, restores mitochondrial integrity and protects the function of vulnerable neurons. NRG5051 has the potential to be a truly disease-modifying medicine, offering a major step forward in our goal to slow or prevent the progression of ALS and other neurodegenerative diseases.”
What comes next and why it stretches beyond ALS
NRG5051 is currently midway through a Phase 1 trial in healthy volunteers, checking safety, tolerability and how the drug moves through the body. Dosing in actual ALS patients is expected before the end of the year, feeding into a Phase 2 proof-of-concept study planned for 2027. The stakes are real: roughly 90% of ALS cases are the sporadic kind with no known genetic cause, and most patients have few treatment options that do more than slow the inevitable.
The longevity angle here isn’t a stretch, either. Mitochondrial decline is one of the most consistently cited hallmarks of aging itself, not just of ALS or Parkinson’s – the two diseases NRG’s pipeline currently targets. As cells lose the ability to generate energy cleanly, tissues across the body become more fragile, inflammation creeps up and recovery slows. A drug that can hold a mitochondrial pore shut in a dying motor neuron is, at least in principle, demonstrating a mechanism that could matter well beyond the neurons it was built to protect. That’s still a long way from proven, but it’s exactly the kind of cross-disease logic that has kept mitochondrial biology near the center of longevity research for the better part of a decade.
